Localized sporotrichosis during natalizumab treatment in Multiple Sclerosis

被引：1
|
作者：
Marques, Paula Teixeira [1 ]
Kay, Claudia Suemi Kamoi [1 ]
Basilio, Flavia Machado Alves [2 ]
Pinheiro, Rosangela Lameira [3 ]
Werneck, Lineu Cesar [1 ]
Lorenzoni, Paulo Jose [1 ]
Scola, Rosana Herminia [1 ]
机构：
[1] Univ Fed Parana UFPR, Hosp Clin, Dept Internal Med, Dept Neurol, Curitiba, Parana, Brazil
[2] Univ Fed Parana UFPR, Hosp Clin, Dept Internal Med, Dept Dermatol, Curitiba, Parana, Brazil
[3] Univ Fed Parana UFPR, Hosp Clin, Mycol Lab, Curitiba, Parana, Brazil
来源：
MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2020年 / 41卷
关键词：
EPIDEMIOLOGY; CELL;
D O I：
10.1016/j.msard.2020.102029
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Natalizumab treatment of multiple sclerosis: new insights
    Delbue, Serena
    Comar, Manola
    Ferrante, Pasquale
    IMMUNOTHERAPY, 2017, 9 (02) : 157 - 171
  • [22] Natalizumab (Tysabri) treatment for relapsing multiple sclerosis
    Johnson, Kenneth P.
    NEUROLOGIST, 2007, 13 (04) : 182 - 187
  • [23] PHARMACOECONOMIC ASSESSMENT OF NATALIZUMAB IN THE TREATMENT OF MULTIPLE SCLEROSIS
    Matveev, N., V
    Sabanov, A., V
    VALUE IN HEALTH, 2012, 15 (04) : A145 - A145
  • [24] Melanoma complicating treatment with natalizumab for multiple sclerosis
    Mullen, John T.
    Vartanian, Timothy K.
    Atkins, Michael B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (06): : 647 - 648
  • [25] Considerations on Discontinuing Natalizumab for the Treatment of Multiple Sclerosis
    Berger, Joseph R.
    Centonze, Diego
    Comi, Giancarlo
    Confavreux, Christian
    Cutter, Gary
    Giovannoni, Gavin
    Gold, Ralf
    Hartung, Hans-Peter
    Lublin, Fred
    Miravalle, Augusto
    Montalban, Xavier
    O'Connor, Paul
    Olsson, Tomas
    Polman, Chris H.
    Stuve, Olaf
    Wolinsky, Jerry S.
    Ziemssen, Tjalf
    ANNALS OF NEUROLOGY, 2010, 68 (03) : 409 - 411
  • [26] Biomarkers for monitoring natalizumab treatment in multiple sclerosis
    Bringeland, G. H.
    Vedeler, C. A.
    Myhr, K. M.
    Gavasso, S.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 901 - 901
  • [27] Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
    O'Connor, P. W.
    Goodman, A.
    Kappos, L.
    Lublin, F. D.
    Miller, D. H.
    Polman, C.
    Rudick, R. A.
    Aschenbach, W.
    Lucas, N.
    NEUROLOGY, 2011, 76 (22) : 1858 - 1865
  • [28] Why patients with multiple sclerosis perceive improvement of gait during treatment with natalizumab?
    Klara Novotna
    Jan Rusz
    Eva Kubala Havrdova
    Jana Lizrova Preiningerova
    Journal of Neural Transmission, 2019, 126 : 731 - 737
  • [29] Treatment with natalizumab during the Covid-19 pandemic in multiple sclerosis patients
    Diaz-Diaz, Judit
    Isabel Ramirez, Clara
    Ortiz-Pica, Marta
    Garcia-Yusta, Elena
    Gomez-Estevez, Irene
    Oreja-Guevara, Celia
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [30] Increase of serum uric acid levels in multiple sclerosis during treatment with natalizumab
    Handouk, Yasmin
    Angeleri, Vita A.
    Danni, Maura
    De Riso, Stella
    Provinciali, Leandro
    MULTIPLE SCLEROSIS, 2008, 14 : S281 - S281
12345